Paragon Care Limited (ASX:PGC)
0.1400
+0.0050 (3.70%)
Sep 18, 2026, 4:10 PM AEST
Paragon Care Revenue
In the fiscal year ending June 30, 2026, Paragon Care had annual revenue of 3.68B AUD with 1.84% growth. Paragon Care had revenue of 1.78B in the half year ending June 30, 2026, with 16.12% growth.
Revenue
3.68B
Revenue Growth
+1.84%
P/S Ratio
0.06
Revenue / Employee
6.69M
Employees
550
Market Cap
231.74M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 3.68B | 66.66M | 1.84% |
| Jun 30, 2025 | 3.61B | 644.00M | 21.68% |
| Jun 30, 2024 | 2.97B | 782.54M | 35.78% |
| Jun 30, 2023 | 2.19B | 479.19M | 28.05% |
| Jun 30, 2022 | 1.71B | 91.10M | 5.63% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 22.83B |
| Ramsay Health Care | 18.58B |
| Sigma Healthcare | 10.83B |
| Mayne Pharma Group | 383.68M |
| Pro Medicus | 261.69M |
| Aroa Biosurgery | 86.47M |
| BLS Pharmaceuticals | 73.91M |
| Actinogen Medical | 12.67M |
Paragon Care News
- 25 days ago - Paragon Care Earnings Call Transcript: H2 2026 - Transcripts
- 25 days ago - Paragon Care Annual report: H2 2026 - Filings
- 25 days ago - Paragon Care Earnings release: H2 2026 - Filings
- 25 days ago - Paragon Care Slides: H2 2026 - Filings
- 6 months ago - Paragon Care Earnings Call Transcript: H1 2026 - Transcripts
- 6 months ago - Paragon Care Quarterly report: H1 2026 - Filings
- 6 months ago - Paragon Care Slides: H1 2026 - Filings
- 6 months ago - Paragon Care Earnings release: H1 2026 - Filings